Michael Ellenbogen, who was diagnosed with younger-onset Alzheimer’s disease in 2008, was invited to give a talk to staff at a major pharma company last week. He has provided his speech to The Pharma Letter as part of his drive for urgent action to defeat the disease. 31 October 2017
Israel’s Teva Pharmaceutical Industries today announced that Kåre Schultz will join the company as president and chief executive, effective November 1, 2017. 31 October 2017
Russia’s leading biotech firm Biocad has confirmed its plans for the building a new pharmaceutical plant in the Finnish city of Turku at the cost of 25 million euros ($29 million), according to the company. 31 October 2017
The Indian government is on the war path again. The Department of Pharmaceuticals is looking to change the method of approving prices of new drugs, despite a clear division in its ranks about amending the drug price control order, in a move that would bring non-essential drugs under price control, reports The Pharma Letter’s India correspondent. 30 October 2017
Japan may have the dubious distinction of being the least understood pharma market in the developed world, writes long-time Japanese industry watcher P Reed Maurer, president of International Alliances Limited, in his exclusive column for The Pharma Letter. 30 October 2017
As with many emerging biotech companies, shares in UK-based Verona Pharma have jumped around a fair bit as markets make their predictions on whether their leading asset is as good as they say it is. 29 October 2017
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion. 27 October 2017
On November 20, the question of which country will host the European Medicines Agency post-Brexit will finally be settled, at the European Council’s General Affairs (Art. 50) meeting. 25 October 2017
Steven Powell, chief executive of UK-based immuno-oncology (I-O) company Macrophage Pharma, gives an overview of developments in this fast-moving space in an Expert View piece. 25 October 2017
Nobody is surprised now when pharma companies that are presenting data at scientific conferences choose to focus on real-world evidence (RWE) as much as, or more than, on their results from randomized control trials. 20 October 2017
Takeda Pharmaceutical, together with Russia’s JSC Pharmstandard, announced the beginning of production of an anti-cancer drug, known as Adzetris (Adcetris: brentuximab vedotin). 18 October 2017
In this week's feature, Michael Jewell, the healthcare partner at Cavendish Corporate Finance, looks at a new initiative by Pfizer, the world’s largest pharmaceutical company, that aims to shake up the way the industry approaches nascent experimental drugs which would otherwise be side-lined. 17 October 2017
Belgian biotech firm Ablynx saw its shares gain 2.3% to 18.28 euros as markets opened this morning and following the announcement that it is establishing a subsidiary in the USA. 16 October 2017
A cloud continues to loom over the implementation of the Unified Patent Convention, a system permitting a single patent covering numerous European countries, writes barrister Mark Engelman, head of intellectual property at UK-based law firm, Hardwicke, in an Expert View piece. 11 October 2017
US pharma major Bristol-Myers Squibb (NYSE: BMY) has appointed scientific and business thought-leader, Saurabh Saha, senior vice president and global head of translational medicine in the company’s R&D organization, effective today. 9 October 2017
Even as French pharma giant Sanofi has stalled development work on a Zika virus vaccine candidate, India is pushing ahead with two vaccine candidates against the virus that continues to cause havoc across the world, and could cause Alzheimer's style symptoms in adults, reports The Pharma Letter’s India correspondent. 9 October 2017
Norbert Oppitz has been appointed senior vice president for the newly-established business area Specialty Care at Nordic drugmaker Swedish Orphan Biovitrum, and will be part of Sobi’s executive leadership team. 6 October 2017
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024